INTRODUCTION
Blood brain barrier (BBB) injury creates a permissive environment for inflammation and the extravasation of immune cells (1) in multiple sclerosis (MS), a chronic inflammatory and neurodegenerative disease of the CNS (2) . Compromised BBB structural integrity is necessary for the formation of contrast-enhancing lesions (CEL), which are frequently found on brain MRI from MS patients even in the absence of clinical relapses. CEL represent focal areas with compromised BBB structural integrity and are associated with parenchymal and meningeal inflammation (3) . Increased BBB water permeability precedes the appearance of CEL and is pervasive in normal-appearing white matter (4) .
In CNS regions with loss of BBB structural integrity, there is increased permeability to macromolecules such as proteins, albumin and immunoglobulins that are normally excluded by the BBB. These macromolecules enter more readily into the CNS and can be detected in CSF. CSF levels of proteins produced exclusively outside the CNS, such as albumin, provide useful surrogate measures of the pathological injury to BBB structural integrity. The presence of T and B cells and immunoglobulins in CSF resulting from extravasation through the BBB provides surrogate measures of immune activity in the CNS. The presence of immunoglobulin oligoclonal bands (OCB) in CSF is used as a paraclinical diagnostic criterion in MS (5) .
Chronic hypercholesterolemia can promote exaggerated immune responses, stronger leukocyte-vascular endothelial cell adhesion and immune cell extravasation in the microvasculature (6, 7) . In this research, we leverage a range of CSF measures to understand the contributions of lipid profile variables to pathophysiological increases in BBB permeability and to immune activity in CSF. We focused on serum cholesterol profiles because there is an emerging body of data suggesting associations between serum cholesterol profiles and MRI measures of lesional and neurodegenerative injury in MS patients (8-13). In our previous work we found an adverse association between greater serum cholesterol and MS disease progression. Higher low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels were by guest, on November 10, 2017 www.jlr.org Downloaded from positively associated with worsening disability measured on the Expanded Disability Status Scale (EDSS) and MS Severity Scale (MSSS) (10, 13). Higher HDL levels were associated with fewer CEL (9, 13). We also investigated the role of cholesterol profiles in patients following the first demyelinating event, prior to disease-modifying treatment, and found that greater LDL-C, TC and ApoB levels were associated with greater number of T2 lesions after 2-years (12, 14). The main goals of this study are to investigate the associations of cholesterol and apolipoprotein levels with CSF-derived measures of increased BBB permeability and cellular and humoral immune activity.
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METHODS

Study Population
Study Setting: Multi-center, prospective, longitudinal observational study.
Informed Consent: The Medical Ethics Committees of the General University Hospital and 1st Faculty of Medicine of Charles University, Prague, Czech Republic, approved the study protocol and the informed consent procedure. Additionally, approvals were obtained from local medical ethics committees of all other participating centers. Written informed consent was obtained from all patients at enrollment.
Clinical Study Design: The Observational Study of Early Interferon beta 1-a Treatment in High Risk
Subjects after Clinically Isolated Syndrome (CIS) (SET study, clin.gov # NCT01592474) and its design have been previously described (15, 16) . This sub-study included 154 patients for whom lipid profiles and CSF-derived measures of increased BBB permeability were available.
Treatments: All patients were treated with 3-5 g of methylprednisolone for the first symptom and baseline MRI was performed ≥ 30 days after steroid administration.
All patients were started on 30 µg, once-weekly, intramuscular interferon beta 1-a (AVONEX ® ) treatment at baseline. 
MRI Acquisition and Analysis
This sub-study was limited to MRI measures obtained at baseline. MRI methods are summarized in Supplementary Methods. We investigated the associations of the number of CEL and T2 lesion volume (LV) at baseline with CSF measures of BBB permeability in statistical analyses.
Serum Lipids and Apolipoproteins
Serum for lipid and apolipoprotein analyses was obtained in the non-fasted state at the screening visit prior to the start of corticosteroid or interferon. The methods for lipid profile and apolipoprotein analyses have been previously described (14) but are succinctly recapitulated here.
Immunoturbidometric diagnostic kits (Kamiya Biomedical, Thousand Oaks, CA) were used for the apolipoprotein (AI, AII, B and E), Lpa and high sensitivity C-reactive protein (CRP) assays. Diagnostic reagent kits (Sekisui Diagnostics, Lexington, MA) were used to measure serum total cholesterol, HDL-C, phospholipids and triglycerides. These assays were conducted on an automated chemistry analyzer (ABX Pentra 400, Horiba Instruments, Irvine, CA). The coefficient of variation of these assays is < 5%. LDL-C was obtained from the Friedewalde equation (17) .
Specific probes for both single nucleotide polymorphisms rs7412 and rs429358 (OpenArray, Applied Biosystems, Life Technologies, Foster City, California, USA) were used to genotype APOE gene variants ε2, ε3 and ε4.
The arylesterase and paraoxonase activities of the human serum paraoxonase-1 (PON1) enzyme were measured using phenyl acetate (arylesterase activity) and paraoxon (paraoxonase activity) as substrates, respectively. The assay CV is 0.6 to 1.4%. The PON1 Q192R polymorphism was obtained from the paraoxonase and arylesterase activities as previously described (18) .
Clinical data collected included height and weight for body mass index (BMI) calculations, and history of statin use. The albumin quotient (Q Alb ) was defined as the ratio of the CSF albumin concentration to the serum albumin concentration (19, 20) :
The IgG Quotient (Q IgG ) and IgM Quotient (Q IgM ) were analogously defined as the ratio of CSF IgG or CSF IgM concentration to their corresponding serum IgG or IgM concentrations:
The IgG index and IgM index, which can be used to assess CSF IgG and IgM synthesis (21), were obtained using the following:
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Isoelectric focusing (IEF) with ultra-sensitive immunofixation (Sebia, Hydrasys Focusing) was used to identify CSF-restricted OCB. 
CSF
RESULTS
Demographic and Clinical Characteristics:
The clinical, demographic and MRI characteristics of the study sample at baseline and the CSF measures and lipid profile variables at screening are summarized in Table 1 .
The mean time ± SD between disease onset and lumbar puncture was 28.2 ± 23.2 days (median = 20.0, inter-quartile range = 34 days). None of the subjects were on statins.
The clinical and demographic characteristics of subjects with lipid profile and CSF measures who were included in the study were similar to the SET study sample that was not included (data not shown). Table 2 summarizes the associations of CSF variables with the serum cholesterol variables (HDL-C, LDL-C, TC), serum apolipoprotein variables (ApoA-I, ApoA-II, ApoB, ApoE) and CRP.
Associations of CSF Variables with Lipid Profile Variables:
Greater HDL-C and TC levels were associated with lower CSF total protein level, CSF albumin level, albumin quotient and CSF IgG level (Table 2) . Additionally, TC was negatively associated with alkaline OCB (23) (p = 0.003, q = 0.007). The CSF variables that were negatively associated with increased TC were also negatively associated with LDL-C with the exception of albumin quotient (q = 0.053).
ApoA-I was associated with the same CSF variables as HDL-C. This provides corroborative support for the HDL-C findings. ApoA-II was associated with CSF IgG levels (p = 0.003, q = 0.036) but no other CSF measures. ApoB and CRP were not associated with any of the CSF variables.
The associations of albumin quotient, IgG Index, IgM Index and CSF leukocytes with HDL-C and ApoA-I are summarized in Figure 1 and Figure 2 , respectively.
Human serum Paraoxonase-1 (PON-1), a hydrolytic enzyme exclusively associated with HDL-C, exhibits a genotype-independent arylesterase activity and a paraoxonase activity that depends on its Q192R
genotype. To further confirm that HDL was associated with protective associations on CSF measures of To assess the relative importance of HDL-C and LDL-C to the associations with CSF variables, we conducted additional regression analyses that included both HDL-C and LDL-C as predictors. In these analyses, the associations of HDL-C with BBB variables remained significant but LDL-C was no longer significant.
Based on the corroborating evidence from the additional regression analyses and the ApoA-I, PONI arylesterase activity and ApoB results, we surmise that the negative associations of TC with albumin quotient, CSF total protein and CSF albumin levels are the result of a salient contribution from HDL-C and that the contributions from LDL-C are potentially secondary in comparison. The negative associations of alkaline OCB with TC are mediated primarily by LDL-C. Both HDL-C and LDL-C appear to contribute to the negative associations of TC with CSF IgG (Table 2 ).
ApoE levels (Table 2) Interestingly, only CD80+CD19+ cell frequencies were associated with ApoB (p < 0.001, q < 0.001).
None of the immune cell subset frequency variables were associated with LDL-C, TC, ApoE or CRP. The associations of CD80+ and CD80+CD19+ cells frequencies and lipid variables HDL-C, ApoA-I and ApoB are summarized in Figure 3 .
The regression results for the cell frequency and lipid profile variables suggest that higher HDL-C levels results in less extravasation of CD80+ and CD80+CD19+ cells into the CSF. There was no evidence for associations of HDL-C levels with CD4+, CCR5+ or CXCR3+ frequencies in CSF.
Associations of CSF Variables with MRI:
We investigated whether CSF measures were associated with baseline CEL number and T2-LV to assess the potential clinical relevance of altered BBB permeability and immune activity. The regression analyses are summarized in supplementary Table 1 .
The mean time ± SD between disease onset and baseline MRI was 82.5 ± 23.6 days (median = 79.0, interquartile range = 37.5 days).
CEL number was associated with all but one of the CSF variables: total protein level, albumin level, Although our results demonstrate protective associations between greater HDL-C levels and lower BBB permeability, the strengths and limitations of our study design merit discussion. The SET study was a well-controlled longitudinal, treatment study that accrued a wealth of clinical MRI and blood biomarkers over a four-year period. However, a potential criticism of the study design is the lack of a placebocontrolled group. A four-year placebo-controlled trial would clearly be ethically infeasible given that proven disease-modifying therapies are now available for MS. However, it would have been useful to compare interferon treatment in the SET trial to a different treatment such as glatiramer acetate to establish whether our results were generalizable to other MS disease-modifying treatments. Our study was also limited because the lipid profile and CSF measures were obtained only at screening making this analysis cross-sectional in nature. Although our statistical results are consistent with a protective role for high HDL levels against BBB injury after the first demyelinating event these associations are not proof of causation.
Our study would be further strengthened if we had also obtained cholesterol and lipoprotein profiles in the CSF. The CSF from SET study patients at the screening visit was primarily used to assess oligoclonal band status of patients for meeting inclusion criteria. Additionally, measures of BBB breakdown and immune cell extravasation were also obtained. Although the CNS and peripheral cholesterol compartments are relatively segregated by the BBB, there is evidence for regulatory interactions and production. Plasma HDL-C has been found to be negatively associated with baseline monocyte counts (30) . HDL-C mediated cholesterol transport also preserves active endothelial nitric oxide synthase (eNOS) dimer levels that maintain endothelial cell function (31) .
The mechanisms by which these protective processes occur in MS remain unknown. Meyers et al, reported that ApoA-I levels were lower in the MS patients compared to healthy controls and the primary progressive MS group had lower levels than relapsing-remitting and secondary-progressive MS groups (32) . Interestingly, in a small study of 36 Alzheimer's disease patients, low HDL was associated with increased BBB breakdown as assessed by albumin quotient (33) . This provides independent evidence, albeit from a different neurological disease, that HDL and lipid profiles can modulate BBB breakdown.
However, Alzheimer's disease is prevalent in the elderly, and 47% of the study group in (33) had metabolic dyslipidemia and 22% were on statins. In contrast, our patient group was younger and none were on statins. Results in the induced experimental allergic encephalomyelitis (EAE) animal model also Multiple groups have independently reported that high LDL-C and TC levels are associated with increased disability and T2 lesion burden (8, 10-13). ApoB, the characteristic protein of LDL-C, was associated with greater CSF CD80+CD19+ cell frequency suggesting a possible role for the LDL compartment in promoting extravasation, proliferation or survival of CD80+CD19+ cells in the CSF milieu. We surmise that while the HDL compartment is important for protecting against increased BBB permeability at the earliest stages of MS, the LDL-C and TC compartments are more important to the subsequent processes that promote T2 lesion burden.
Our results indicate a protective role for HDL-C in the pathophysiological BBB injury that precedes the formation of MS lesions. The findings are consistent with the intriguing possibility that loss of BBB structural integrity is nucleated in membrane sub-domains actively involved in cholesterol homeostasis or at pathophysiologically dyslipidemic tissue regions. 
TABLES
